On the ‘micro’-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action

Introduction: Optimal drug therapy often requires continuing high levels of target occupancy. Besides the traditional pharmacokinetic (PK) contribution thereto, drug–target interactions that comprise successive ‘microscopic’ steps as well as the intervention of the cell membrane and other ‘micro’-anatomical structures nearby may help attaining this objective. Areas covered: This article reviews the ‘micro’-pharmacodynamic (PD) and PK mechanisms that may increase a drug’s residence time. Special focus is on induced-fit- and bivalent ligand binding models as well as on the ability of the plasma membrane surrounding the target to act as a repository for the drug (e.g., microkinetic model), to actively participate in the binding process (e.g., exosite model) and, along with microanatomical elements like synapses and interstitial spaces, to act on the drug’s diffusion properties (reduction in dimensionality and drug-rebinding models). Expert opinion: The PK profile, as well as the target dissociation kinetics of a drug, may fail to account for its long-lasting efficiency in intact tissues and in vivo. This lacuna could potentially be alleviated by incorporating some of the enumerated ‘microscopic’ mechanisms and, to unveil them, dedicated experiments on sufficiently physiologically relevant biological material like cell monolayers can already be implemented early on in the lead optimization process.

[1]  S. Charlton,et al.  ‘Partial’ competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models , 2015, British journal of pharmacology.

[2]  M. H. Santana,et al.  Receptor-mediated biological responses are prolonged using hydrophobized ligands. , 2004, Biosensors & bioelectronics.

[3]  G. Anderson Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. , 1993, Life sciences.

[4]  Anatoly B Kolomeisky,et al.  Physics of protein-DNA interactions: mechanisms of facilitated target search. , 2011, Physical chemistry chemical physics : PCCP.

[5]  D. Swinney Can Binding Kinetics Translate to a Clinically Differentiated Drug? From Theory to Practice , 2006 .

[6]  G. Vauquelin Determination of drug–receptor residence times by radioligand binding and functional assays: experimental strategies and physiological relevance , 2012 .

[7]  R. Schwyzer 100 Years lock‐and‐key concept: Are peptide keys shaped and guided to their receptors by the target cell membrane? , 1995, Biopolymers.

[8]  G. Vauquelin,et al.  Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor , 2007, British journal of pharmacology.

[9]  G. Vauquelin,et al.  Estimation of the dissociation rate of unlabelled ligand–receptor complexes by a ‘two‐step’ competition binding approach , 2010, British journal of pharmacology.

[10]  Adriaan P IJzerman,et al.  Drug‐Target Residence Time—A Case for G Protein‐Coupled Receptors , 2014, Medicinal research reviews.

[11]  G. Vauquelin,et al.  Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands , 2014, Fundamental & clinical pharmacology.

[12]  E. Garvey Structural Mechanisms of Slow-Onset, Two-Step Enzyme Inhibition , 2010 .

[13]  G. Dahl,et al.  Pharmacokinetics and the drug-target residence time concept. , 2013, Drug discovery today.

[14]  D. Sargent,et al.  Membrane lipid phase as catalyst for peptide-receptor interactions. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D C Swinney,et al.  Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines , 2013, Clinical pharmacology and therapeutics.

[16]  P. Morsing,et al.  Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. , 1999, Hypertension.

[17]  Tod D Romo,et al.  A Lipid Pathway for Ligand Binding Is Necessary for a Cannabinoid G Protein-coupled Receptor* , 2010, The Journal of Biological Chemistry.

[18]  Jianfeng Pei,et al.  A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular and systems levels. , 2013, Molecular bioSystems.

[19]  U. Holzgrabe,et al.  Rational design of dualsteric GPCR ligands: quests and promise , 2010, British journal of pharmacology.

[20]  P. Leff,et al.  The two-state model of receptor activation. , 1995, Trends in pharmacological sciences.

[21]  W. Sadee,et al.  [3H]diprenorphine receptor binding in vivo and in vitro. , 1982, European journal of pharmacology.

[22]  T. Kenakin,et al.  Determining the Potency and Molecular Mechanism of Action of Insurmountable Antagonists , 2006, Journal of Pharmacology and Experimental Therapeutics.

[23]  G. Vauquelin Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time , 2010, Expert opinion on drug discovery.

[24]  D. Swinney The role of binding kinetics in therapeutically useful drug action. , 2009, Current opinion in drug discovery & development.

[25]  G. Vauquelin,et al.  Sartan–AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism , 2009, Molecular and Cellular Endocrinology.

[26]  Susan M Abdel-Rahman,et al.  The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. , 2004, Annual review of pharmacology and toxicology.

[27]  M. Johnson Beta2-adrenoceptors: mechanisms of action of beta2-agonists. , 2001, Paediatric respiratory reviews.

[28]  Dieter M. Tourlousse,et al.  Effect of saponin and filipin on antagonist binding to AT 1 receptors in intact cells. , 2004, Biochemical pharmacology.

[29]  Hartmut Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development , 2000, Journal of clinical pharmacology.

[30]  T. Mavromoustakos,et al.  Comparative biophysical studies of sartan class drug molecules losartan and candesartan (CV-11974) with membrane bilayers. , 2011, The journal of physical chemistry. B.

[31]  N. Volkow,et al.  Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high‐affinity PET and SPECT radiotracers , 1998, Synapse.

[32]  Arthur Christopoulos,et al.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology , 2003, Pharmacological Reviews.

[33]  M. Castanho,et al.  Lipid membrane-induced optimization for ligand–receptor docking: recent tools and insights for the “membrane catalysis” model , 2005, European Biophysics Journal.

[34]  George E. P. Box,et al.  Evolutionary Operation: A Statistical Method for Process Improvement , 1969 .

[35]  L B Sheiner,et al.  Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.

[36]  S. Charlton,et al.  Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands , 2013, British journal of pharmacology.

[37]  L. Herbette Membrane pathways for drug/ion channel interactions: Molecular basis for pharmacokinetic properties , 1994 .

[38]  J. Biollaz,et al.  Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. , 1995, Hypertension.

[39]  M. Dembo,et al.  Approximating the effects of diffusion on reversible reactions at the cell surface: ligand-receptor kinetics. , 1995, Biophysical journal.

[40]  Robert A Copeland,et al.  The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety , 2010, Expert opinion on drug discovery.

[41]  H R Hoogenboom,et al.  Design and application of diabodies, triabodies and tetrabodies for cancer targeting. , 2001, Journal of immunological methods.

[42]  G. Vauquelin Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time , 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.

[43]  Oliver P. Ernst,et al.  A Ligand Channel through the G Protein Coupled Receptor Opsin , 2009, PloS one.

[44]  G. Vauquelin,et al.  Molecular mechanisms for the persistent bronchodilatory effect of the β2‐adrenoceptor agonist salmeterol , 2009, British journal of pharmacology.

[45]  A. Vasudevan,et al.  Design strategies to address kinetics of drug binding and residence time. , 2015, Bioorganic & medicinal chemistry letters.

[46]  A. IJzerman,et al.  Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor , 2014, British journal of pharmacology.

[47]  V. Massey,et al.  Determination of dissociation constants and specific rate constants of enzyme-substrate (or protein-ligand) interactions from rapid reaction kinetic data. , 1975, The Journal of biological chemistry.

[48]  G. Vauquelin,et al.  Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. , 1999, European journal of pharmacology.

[49]  M. Johnson,et al.  Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. , 1996, Molecular pharmacology.

[50]  G. Vauquelin,et al.  Ligands, their receptors and … plasma membranes , 2009, Molecular and Cellular Endocrinology.

[51]  G. Vauquelin,et al.  A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists. , 2001, Biochemical pharmacology.

[52]  S. Charlton,et al.  Slow receptor dissociation is not a key factor in the duration of action of inhaled long‐acting β2‐adrenoceptor agonists , 2012, British journal of pharmacology.

[53]  K. Kubo,et al.  Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. , 1997, European journal of pharmacology.

[54]  M. Eigen Diffusion Control in Biochemical Reactions , 1974 .

[55]  M. Lohse,et al.  Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Kramer,et al.  Spanning binding sites on allosteric proteins with polymer-linked ligand dimers , 1998, Nature.

[57]  John Reilly,et al.  Observed Drug-Receptor Association Rates Are Governed by Membrane Affinity: The Importance of Establishing “Micro-Pharmacokinetic/Pharmacodynamic Relationships” at the β2-Adrenoceptor , 2014, Molecular Pharmacology.

[58]  G. Vauquelin,et al.  Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems , 2012, Expert opinion on drug discovery.

[59]  B. Goldstein,et al.  Effects of the geometry of the immunological synapse on the delivery of effector molecules. , 2004, Biophysical journal.

[60]  S. Hoare Allosteric Modulators of Class B G-Protein-Coupled Receptors , 2007, Current neuropharmacology.

[61]  Rocha e Silva A thermodynamic approach to problems of drug antagonism I. The "Charnière theory". , 1969, European Journal of Pharmacology.

[62]  J. Jakubík,et al.  Role of Receptor Protein and Membrane Lipids in Xanomeline Wash-Resistant Binding to Muscarinic M1 Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.

[63]  R. Shrager,et al.  Diffusion delays and unstirred layer effects at monolayer cultures of Chinese hamster ovary cells , 2006, Cell Biochemistry and Biophysics.

[64]  S. Widmayer,et al.  Quantum Statistical Mechanics in the Natural Sciences , 1974, Studies in the Natural Sciences.

[65]  S. Green,et al.  Sustained Activation of a G Protein-coupled Receptor via “Anchored” Agonist Binding , 1996, The Journal of Biological Chemistry.

[66]  M. Johnson,et al.  Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. , 1996, Trends in pharmacological sciences.

[67]  D. Myszka,et al.  Probing the mechanism of drug/lipid membrane interactions using Biacore. , 2004, Analytical biochemistry.

[68]  Arthur Christopoulos,et al.  Bridging the gap: bitopic ligands of G-protein-coupled receptors. , 2013, Trends in pharmacological sciences.

[69]  Hugh Rosen,et al.  Crystal Structure of a Lipid G Protein–Coupled Receptor , 2012, Science.

[70]  D. Rhodes,et al.  Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. , 1991, Journal of medicinal chemistry.

[71]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[72]  N. Birdsall,et al.  Modification of the binding properties of muscarinic receptors by gallamine. , 1983, Molecular pharmacology.

[73]  D. Swinney,et al.  A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands , 2014, British journal of pharmacology.

[74]  P. Sexton,et al.  The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. , 2012, Annual review of pharmacology and toxicology.

[75]  George M Whitesides,et al.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.

[76]  M. Trevethick,et al.  The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor. , 2011, Pulmonary pharmacology & therapeutics.

[77]  R. Copeland,et al.  Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.

[78]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[79]  D. Swinney,et al.  Biochemical mechanisms of drug action: what does it take for success? , 2004, Nature Reviews Drug Discovery.

[80]  G. Vauquelin,et al.  Binding of the antagonist []candesartan to angiotensin II AT1 receptor-tranfected Chinese hamster ovary cells , 1999 .

[81]  G. Vauquelin,et al.  Slow antagonist dissociation and long-lasting in vivo receptor protection. , 2006, Trends in pharmacological sciences.

[82]  P. Molinoff,et al.  Fundamental difference between the molecular interactions of agonists and antagonists with the β-adrenergic receptor , 1979, Nature.

[83]  Terry Kenakin,et al.  Ligand-selective receptor conformations revisited: the promise and the problem. , 2003, Trends in pharmacological sciences.

[84]  S. Charlton,et al.  Long‐lasting target binding and rebinding as mechanisms to prolong in vivo drug action , 2010, British journal of pharmacology.

[85]  Frederick Monsma,et al.  The importance of drug-target residence time. , 2009, Current opinion in drug discovery & development.

[86]  R. Mansi,et al.  Hybrid bombesin analogues: combining an agonist and an antagonist in defined distances for optimized tumor targeting. , 2013, Journal of the American Chemical Society.

[87]  G. Müller,et al.  Mapping of ligand binding sites of the cholecystokinin-B/gastrin receptor with lipo-gastrin peptides and molecular modeling. , 1997, Biopolymers.

[88]  A. Plückthun,et al.  New protein engineering approaches to multivalent and bispecific antibody fragments. , 1997, Immunotechnology : an international journal of immunological engineering.

[89]  G. Vauquelin,et al.  Models and methods for studying insurmountable antagonism. , 2002, Trends in pharmacological sciences.

[90]  G. Vauquelin,et al.  Distinct binding properties of the AT(1) receptor antagonist [(3)H]candesartan to intact cells and membrane preparations. , 2002, Biochemical pharmacology.

[91]  G. Adams,et al.  Affinity and avidity in antibody-based tumor targeting. , 2009, Cancer biotherapy & radiopharmaceuticals.

[92]  P. Tonge,et al.  Drug-target residence time: critical information for lead optimization. , 2010, Current opinion in chemical biology.

[93]  Jennifer Venhorst,et al.  Target-drug interactions: first principles and their application to drug discovery. , 2012, Drug discovery today.

[94]  R. Austin,et al.  QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists. , 2003, Journal of medicinal chemistry.

[95]  Albert C. Pan,et al.  Pathway and mechanism of drug binding to G-protein-coupled receptors , 2011, Proceedings of the National Academy of Sciences.

[96]  T. Kenakin Cellular assays as portals to seven-transmembrane receptor-based drug discovery , 2009, Nature Reviews Drug Discovery.

[97]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[98]  M. Poo,et al.  Rates of membrane-associated reactions: reduction of dimensionality revisited , 1986, The Journal of cell biology.

[99]  R. Copeland Conformational adaptation in drug-target interactions and residence time. , 2011, Future medicinal chemistry.